Exelixis (EXEL) News Today $36.20 -0.35 (-0.96%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today?January 20 at 11:31 AM | finance.yahoo.comAssenagon Asset Management S.A. Decreases Holdings in Exelixis, Inc. (NASDAQ:EXEL)Assenagon Asset Management S.A. decreased its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 80.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 221,913 shares of the biotechnology company's stock after selling 889,445 sharJanuary 20 at 3:22 AM | marketbeat.comExelixis (NASDAQ:EXEL) Price Target Raised to $41.00January 19 at 3:57 AM | americanbankingnews.comFY2024 EPS Estimates for Exelixis Lifted by Leerink PartnrsJanuary 19 at 2:15 AM | americanbankingnews.comJMP Securities Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockJanuary 18 at 2:51 AM | americanbankingnews.comBalanced Risk and Reward for Exelixis Amid Uncertain Prospects for ZanzalintinibJanuary 17, 2025 | markets.businessinsider.comExelixis’s Strategic Outlook and Prudence Amid Mixed Financial ProjectionsJanuary 17, 2025 | markets.businessinsider.comFY2024 EPS Estimates for Exelixis Increased by AnalystExelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at Leerink Partnrs increased their FY2024 earnings estimates for Exelixis in a research note issued to investors on Wednesday, January 15th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will post earnJanuary 17, 2025 | marketbeat.comTallon Kerry Patrick Acquires Shares of 77,166 Exelixis, Inc. (NASDAQ:EXEL)Tallon Kerry Patrick acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 77,166 shares of the biotechnology company's stock, valued at approximatelyJanuary 17, 2025 | marketbeat.comFY2025 EPS Estimates for Exelixis Raised by William BlairJanuary 17, 2025 | americanbankingnews.comOppenheimer Remains a Buy on Exelixis (EXEL)January 16, 2025 | markets.businessinsider.comExelixis (NASDAQ:EXEL) Given New $41.00 Price Target at OppenheimerOppenheimer upped their price target on Exelixis from $38.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday.January 16, 2025 | marketbeat.comExelixis price target raised to $41 from $38 at OppenheimerJanuary 16, 2025 | msn.comOppenheimer bullish on Exelixis stock as cabo sales and R&D progress impressJanuary 16, 2025 | msn.comExelixis (NASDAQ:EXEL) Sets New 12-Month High After Analyst UpgradeJanuary 16, 2025 | americanbankingnews.comWilliam Blair Issues Positive Forecast for Exelixis EarningsJanuary 16, 2025 | americanbankingnews.comExelixis price target raised to $41 from $34 at JMP SecuritiesJanuary 15, 2025 | markets.businessinsider.comExelixis (EXEL) Receives a Buy from Truist FinancialJanuary 15, 2025 | markets.businessinsider.comExelixis (NASDAQ:EXEL) Hits New 52-Week High on Analyst UpgradeExelixis (NASDAQ:EXEL) Sets New 52-Week High on Analyst UpgradeJanuary 15, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Stock Price Expected to Rise, JMP Securities Analyst SaysJMP Securities boosted their target price on Exelixis from $34.00 to $41.00 and gave the stock a "market outperform" rating in a report on Wednesday.January 15, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Price Target Raised to $42.00Truist Financial increased their price target on Exelixis from $38.00 to $42.00 and gave the stock a "buy" rating in a report on Wednesday.January 15, 2025 | marketbeat.comBurney Co. Acquires New Position in Exelixis, Inc. (NASDAQ:EXEL)Burney Co. bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 368,373 shares of the biotechnology company's stock, valued at approximately $12,267,000. Burney Co. owneJanuary 15, 2025 | marketbeat.comFY2025 EPS Estimates for Exelixis Boosted by William BlairExelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities research analysts at William Blair upped their FY2025 earnings per share estimates for Exelixis in a research note issued on Sunday, January 12th. William Blair analyst A. Hsieh now anticipates that the biotechnology company will post earningsJanuary 15, 2025 | marketbeat.comZacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint MedicinesJanuary 15, 2025 | uk.finance.yahoo.comJMP Securities Remains a Buy on Exelixis (EXEL)January 15, 2025 | markets.businessinsider.comExelixis: Truist raises price target citing increased sales potentialJanuary 15, 2025 | in.investing.comExelixis (NASDAQ:EXEL) Stock Price Expected to Rise, Piper Sandler Analyst SaysJanuary 15, 2025 | americanbankingnews.comWilliam Blair Analysts Lift Earnings Estimates for ExelixisExelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for Exelixis in a report issued on Sunday, January 12th. William Blair analyst A. Hsieh now anticipates that the biotechnology company will earn $1.74 per shareJanuary 14, 2025 | marketbeat.comExelixis price target raised to $37 from $36 at Piper SandlerJanuary 13, 2025 | markets.businessinsider.comExelixis (EXEL) Receives a Hold from Bank of America SecuritiesJanuary 13, 2025 | markets.businessinsider.comExelixis (NASDAQ:EXEL) Price Target Raised to $37.00 at Piper SandlerPiper Sandler upped their price target on shares of Exelixis from $36.00 to $37.00 and gave the stock an "overweight" rating in a research note on Monday.January 13, 2025 | marketbeat.comExelixis: Hold Rating Amid Stable Performance and Moderate Growth ExpectationsJanuary 13, 2025 | markets.businessinsider.comExelixis reports preliminary FY24 revenue $2.165B, consensus $2.16BJanuary 13, 2025 | markets.businessinsider.comExelixis sets 2025 guidance in line with estimatesJanuary 13, 2025 | msn.comExelixis Inc (EXEL) Announces Preliminary 2024 Financial Results and 2025 GuidanceJanuary 12, 2025 | gurufocus.comExelixis Inc (EXEL) Announces Preliminary 2024 Financial Results and 2025 GuidanceJanuary 12, 2025 | gurufocus.comExelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025January 12, 2025 | businesswire.comHC Wainwright Raises Exelixis (NASDAQ:EXEL) Price Target to $40.00January 12, 2025 | americanbankingnews.comExelixis price target raised to $40 from $29 at H.C. WainwrightJanuary 11, 2025 | markets.businessinsider.comExelixis says cabozantinib sNDA no longer Advisory Committee discussion subjectJanuary 10, 2025 | markets.businessinsider.comNo FDA advisory meeting for Exelixis a positive, says CitiJanuary 10, 2025 | markets.businessinsider.comHC Wainwright Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock PriceHC Wainwright lifted their price target on shares of Exelixis from $29.00 to $40.00 and gave the company a "buy" rating in a research note on Friday.January 10, 2025 | marketbeat.comExelixis Notified by FDA That Cabozantinib Application Won't Be Discussed at MeetingJanuary 9, 2025 | marketwatch.comExelixis says no FDA AdCom for Cabometyx label expansionJanuary 9, 2025 | msn.comExelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, ZanzaJanuary 9, 2025 | seekingalpha.comExelixis price target raised to $42 from $33 at GuggenheimJanuary 7, 2025 | markets.businessinsider.comRange Financial Group LLC Invests $994,000 in Exelixis, Inc. (NASDAQ:EXEL)Range Financial Group LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 29,855 shares of the biotechnology companyJanuary 7, 2025 | marketbeat.comGuggenheim Boosts Exelixis (NASDAQ:EXEL) Price Target to $42.00Guggenheim upped their price objective on Exelixis from $33.00 to $42.00 and gave the company a "buy" rating in a research report on Tuesday.January 7, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by BrokeragesShares of Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nineteen research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have given a holJanuary 5, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. lowered its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 12.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,430,653 shares of the biotechnoloJanuary 2, 2025 | marketbeat.com Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Media Mentions By Week EXEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼0.610.46▲Average Medical News Sentiment EXEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼4010▲EXEL Articles Average Week Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Biogen News United Therapeutics News Neurocrine Biosciences News Incyte News BioMarin Pharmaceutical News Exact Sciences News Repligen News Halozyme Therapeutics News Madrigal Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
